Medicaid Preferred Drug List (PDL) Supplemental Rebate Bid Positioning Analysis
Our Medicaid Preferred Drug List (PDL) Supplemental Rebate Bid Positioning Analyses provides clients with an in-depth analytical view of the category to provide them with the necessary information to make an informed decision on whether or not to participate in the bid and what level of rebate is necessary to provide a competitive offer. Medicaid Predictive Rebate Modeling
Our Predictive Rebate Modeling (PRM) analysis assists manufacturers with developing competitive rebate structures to optimize Medicaid preferred drug list positioning. The PRM analysis process thoroughly examines the cost structure and market share dynamics of the category, and it mimics many of the review techniques administered by the state or Preferred Drug List vendor. This minimizes the client’s rebate exposure, while also obtaining optimal Preferred Drug List positioning. Medicaid Gross-to-Net (ROI) Revenue Modeling
We’re able to accurately forecast rebate liabilities, and we apply these principles to understand the potential impact of government contract decisions. By forecasting whether or not paying a greater rebate for “preferred” status on a formulary will have a little or large impact on sales volume and market share, we place our clients in a profitable position by minimizing their rebates and improving their net selling price. Medicaid Price Increase and Unit Rebate Impact Forecasting
In the competitive prescription drug marketplace, manufacturers routinely take price increases on their products, which results in increased returns in the commercial sector. However, price increases can create negative pressure on Medicaid rebates through the “CPI-Penalty” formulas required in the Medicaid rebate calculation. We’ve found it necessary to assist clients in evaluating these price increases and analyzing potential impacts on net revenue and Medicaid access for their products. Medicaid Utilization and Cost Data Reporting
We can also provide custom reports upon request. These reports are developed from our database, which contains more than five years of Medicaid drug utilization data.